JPH1036346A5 - - Google Patents

Info

Publication number
JPH1036346A5
JPH1036346A5 JP1997101563A JP10156397A JPH1036346A5 JP H1036346 A5 JPH1036346 A5 JP H1036346A5 JP 1997101563 A JP1997101563 A JP 1997101563A JP 10156397 A JP10156397 A JP 10156397A JP H1036346 A5 JPH1036346 A5 JP H1036346A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
azepan
indol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997101563A
Other languages
English (en)
Japanese (ja)
Other versions
JPH1036346A (ja
JP4093611B2 (ja
Filing date
Publication date
Priority claimed from US08/833,271 external-priority patent/US5998402A/en
Application filed filed Critical
Publication of JPH1036346A publication Critical patent/JPH1036346A/ja
Publication of JPH1036346A5 publication Critical patent/JPH1036346A5/ja
Application granted granted Critical
Publication of JP4093611B2 publication Critical patent/JP4093611B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP10156397A 1996-04-19 1997-04-18 エストロゲン剤 Expired - Lifetime JP4093611B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63397496A 1996-04-19 1996-04-19
US08/633974 1997-04-04
US08/833271 1997-04-04
US08/833,271 US5998402A (en) 1996-04-19 1997-04-04 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents

Publications (3)

Publication Number Publication Date
JPH1036346A JPH1036346A (ja) 1998-02-10
JPH1036346A5 true JPH1036346A5 (enExample) 2008-02-14
JP4093611B2 JP4093611B2 (ja) 2008-06-04

Family

ID=27092026

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10156397A Expired - Lifetime JP4093611B2 (ja) 1996-04-19 1997-04-18 エストロゲン剤

Country Status (26)

Country Link
EP (1) EP0802183B1 (enExample)
JP (1) JP4093611B2 (enExample)
KR (1) KR100480193B1 (enExample)
CN (1) CN1106383C (enExample)
AR (1) AR011503A1 (enExample)
AT (1) ATE206701T1 (enExample)
AU (1) AU710149B2 (enExample)
BR (1) BRPI9715334B8 (enExample)
CO (1) CO4900051A1 (enExample)
CY (2) CY2325B1 (enExample)
CZ (1) CZ291701B6 (enExample)
DE (2) DE69707189T2 (enExample)
DK (1) DK0802183T3 (enExample)
EA (1) EA001448B1 (enExample)
ES (1) ES2162198T3 (enExample)
FR (1) FR09C0048I2 (enExample)
HU (1) HU227077B1 (enExample)
IL (1) IL120701A (enExample)
LU (1) LU91608I2 (enExample)
MX (1) MX9702865A (enExample)
NL (1) NL300416I2 (enExample)
NO (2) NO309564B1 (enExample)
NZ (1) NZ314601A (enExample)
PT (1) PT802183E (enExample)
SK (1) SK281737B6 (enExample)
UA (1) UA48148C2 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048797A1 (en) * 1997-04-30 1998-11-05 Eli Lilly And Company Antithrombotic agents
CA2287984A1 (en) 1997-05-01 1998-11-05 Gerald Floyd Smith Antithrombotic agents
UA68365C2 (en) * 1997-11-06 2004-08-16 Wyeth Corp Peroral contraception by combination of anti-estrogen and progestin
US6069153A (en) * 1998-05-12 2000-05-30 American Home Products Corporation Indenoindoles and benzocarbazoles as estrogenic agents
AU3894399A (en) * 1998-05-12 1999-11-29 American Home Products Corporation Benzocarbazole and indenoindole derived estrogenic agents
CN1309637A (zh) * 1998-05-15 2001-08-22 美国家用产品公司 包含2－苯基－吲哚化合物和雌激素制剂的组合物
HRP20000778B1 (en) * 1998-05-15 2004-10-31 Wyeth Corp 2-phenyl-1-/4-(2-aminoethoxy)-benzyl/-indole in combination with estrogens
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
ES2213984T3 (es) * 1998-10-30 2004-09-01 Eli Lilly And Company Derivados de azaindol y su uso como agentes antitrombicos.
US6380185B1 (en) 1999-03-04 2002-04-30 American Home Products Corporation N-substituted benzoyl indoles as estrogenic agents
TWI220898B (en) * 1999-03-04 2004-09-11 Wyeth Corp N-substituted indolines as estrogenic agents
JP2002538141A (ja) * 1999-03-04 2002-11-12 ワイス エストロゲン剤としてのｎ−置換ベンゾイルインドール
US6358943B1 (en) 1999-03-04 2002-03-19 American Home Products Corporation N-substituted indolines as estrogenic agents
US6380166B1 (en) 1999-09-13 2002-04-30 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
DK1212335T3 (da) * 1999-09-13 2006-03-20 Wyeth Corp Glucopyranosid-konjugater af 2-(4-hydroxyphenyl)-1-[4-(2-amin-1-ylethoxy)-benzyl]-1H-indol-5-oler
AU2991301A (en) * 2000-01-28 2001-08-07 Endorecherche Inc. Selective estrogen receptor modulators in combination with estrogens
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
AR030064A1 (es) * 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
EP1311293A2 (en) 2000-07-06 2003-05-21 Wyeth Combinations of ssri and estrogenic agents
WO2002003992A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating prosthesis-related bone degeneration
WO2002003990A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted insole compounds for treating excessive intraocular pressure
WO2002003991A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for increasing nitric oxide synthase activity
US6358991B2 (en) * 2000-07-06 2002-03-19 American Home Products Corporation Methods of treating neuropeptide Y-related conditions
EP1656938A1 (en) 2000-07-06 2006-05-17 Wyeth Combinations of SSRI and estrogenic agents
WO2002003986A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating breast disorders
AU2001271781A1 (en) * 2000-07-06 2002-01-21 Wyeth Use of substituted indole compounds for treating sphincter incontinence
EP1177787A3 (en) * 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
DE60210283T2 (de) 2001-05-22 2006-11-09 Eli Lilly And Co., Indianapolis 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren
ES2236536T3 (es) 2001-05-22 2005-07-16 Eli Lilly And Company Derivados tetrahidroquinolino para la inhibicion de enfermedades asociadas con la privacion de estrogenos o con una respuesta fisiologica aberrante a estrogenos endogenos.
US20040063692A1 (en) * 2002-06-13 2004-04-01 Wyeth Bazedoxifene treatment regimens
ES2326593T3 (es) 2002-07-22 2009-10-15 Eli Lilly And Company Moduladores de receptores de estrogeno selectivos que contienen un grupo fenilsulfonilo.
WO2004058682A1 (ja) 2002-12-26 2004-07-15 Eisai Co., Ltd. 選択的エストロゲン受容体モジュレーター
US7250440B2 (en) * 2003-08-12 2007-07-31 Wyeth (Hydroxyphenyl)-1H-indole-3-carbaldehyde oxime derivatives as estrogenic agents
TWI346105B (en) 2004-04-07 2011-08-01 Wyeth Corp Crystalline polymorph of bazedoxifene acetate
GT200500080A (es) 2004-04-07 2005-10-31 Polimorfo cristalino de acetato de bazedoxifeno
KR20060134146A (ko) 2004-04-08 2006-12-27 와이어쓰 선택적 에스트로겐 수용체 모듈레이터로서의 바제독시펜아스코르베이트
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EA200700243A1 (ru) 2004-07-14 2007-08-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения гепатита с
CA2578636A1 (en) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating hepatitis c
CN1993322A (zh) * 2004-08-05 2007-07-04 惠氏公司 哌多昔芬盐酸盐一水合物的结晶多晶型物
MX368189B (es) 2004-10-20 2019-09-23 Endorecherche Inc Precursores esteroides sexuales solos o en combinación con un modulador receptor de estrógeno selectivo y/o con estrógenos y/o con un inhibidor de fosfodiesterasa gmpc de tipo 5 para la prevención y tratamiento de sequedad vaginal y disfunción sexual en mujeres post-menopáusicas.
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
US20100087661A1 (en) * 2007-02-12 2010-04-08 Josef Jirman Method for the preparation of 5-benzyloxy-2-(4-benzyloxphenyl)-3-methyl-1h-indole
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
JP5199395B2 (ja) * 2008-02-11 2013-05-15 ワイス・エルエルシー バゼドキシフェン酢酸塩の多形体ａの調製方法
CN102066323B (zh) 2008-04-16 2015-05-13 卡罗生物股份公司 新的雌激素受体配体
RU2011145811A (ru) * 2009-04-13 2013-05-20 Сандоз Аг Способы синтеза базедоксифенацетата и его промежуточных продуктов
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
WO2011156908A1 (en) 2010-06-16 2011-12-22 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases
US7968732B1 (en) 2010-09-07 2011-06-28 Divi's Laboratories, Ltd. Process for the preparation of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole
WO2012037187A2 (en) 2010-09-14 2012-03-22 Dr. Reddy's Laboratories Ltd. Preparation of crystalline bazedoxifene and its salts
US8569483B2 (en) 2011-06-21 2013-10-29 Divi's Laboratories, Ltd. Process for the preparation of bazedoxifene acetate and intermediates thereof
CN102690225B (zh) * 2012-04-11 2014-12-24 南京友杰医药科技有限公司 巴多昔芬的合成方法
WO2014186325A1 (en) * 2013-05-15 2014-11-20 Indiana University Research And Technology Corporation Processes and intermediates for preparing indole pharmaceuticals
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
PT3122426T (pt) 2014-03-28 2023-02-28 Univ Duke Tratamento de cancro da mama utilizando moduladores seletivos do recetor de estrogénio
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
US9845291B2 (en) * 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
KR20190110400A (ko) 2018-03-20 2019-09-30 엠에프씨 주식회사 새로운 중간체를 이용한 바제독시펜의 제조방법
IT201800006562A1 (it) * 2018-06-21 2019-12-21 Procedimento e intermedi utili per la preparazione di indoli
IT201900001923A1 (it) 2019-02-11 2020-08-11 Erregierre Spa Sali di bazedoxifene utili per la preparazione di bazedoxifene acetato
US11246874B1 (en) 2021-04-20 2022-02-15 Oxygen Biotech LLC Treatment of COVID-19

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU373941A3 (enExample) * 1970-01-21 1973-03-12
DE2557342A1 (de) * 1975-12-19 1977-06-30 Hoechst Ag Basisch substituierte indolderivate und verfahren zu ihrer herstellung
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
DE3232968A1 (de) * 1981-09-10 1983-06-09 Degussa Ag, 6000 Frankfurt Neue 2-(hydroxy-phenyl)-indole und verfahren zu deren herstellung
CA1241660A (en) * 1984-06-25 1988-09-06 Yvan Guindon Indole-2-alkanoic acids
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
DE3821148A1 (de) * 1988-06-23 1989-12-28 Erwin Von Dr Angerer Aminoalkylindole, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
GB9004301D0 (en) * 1990-02-26 1990-04-18 Fujisawa Pharmaceutical Co Indolebutyric acid derivatives and process for preparation thereof
US5051442A (en) * 1990-04-25 1991-09-24 Merrell Dow Pharmaceuticals Inc. 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof
KR950701317A (ko) * 1992-05-08 1995-03-23 오오쓰까 아끼히꼬 인돌 유도체(Indole Derivative)
DE69422450T2 (de) * 1993-06-29 2000-06-08 Takeda Chemical Industries, Ltd. Chinoline oder Chinazolin-Derivate und deren Verwendung zur Herstellung eines Medikaments für die Behandlung von Osteoporose
GB9326332D0 (en) * 1993-12-23 1994-02-23 Karo Bio Indole derivatives
DE4426625A1 (de) * 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln

Similar Documents

Publication Publication Date Title
JPH1036346A5 (enExample)
NO20004915L (no) Transdermalt terapeutisk system som inneholder en D2-agonist og som tilveiebringes for behandling av Parkinsons sykdom og en fremgangsmÕte for dets fremstilling
HUP0101434A3 (en) Sulfonamide-containing indole compounds, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing the same
JPH11514367A5 (enExample)
LU92428I2 (fr) Bosutinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable
HUP9701694A3 (en) Indolinone derivatives for the treatment of disease, use thereof, pharmaceutical compositions containing these compounds
NO972679D0 (no) Fremgangsmåte for fremstilling av 1-(2'-deoksy-2',2'-difluor-D-ribofuranosyl-4-aminopyrimidin-2-on)hydroklorid
HUP9700777A3 (en) Estrogenical 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole derivatives, preparation and use thereof and pharmaceutical compositions containing these compounds
MA26523A1 (fr) Modification thermodynamiquement stable de 1-(4-carbazolyloxy)-3-(2-(2-methoxyphenoxy) ethylamino)-2-propanole, procede pour sa preparation et compositions pharmaceutiques le comprenant
ZA9911B (en) 2,3-substituted indole compounds as anti-inflammatory and analgesic agents.
WO1999044608A8 (en) New use
NO970036D0 (no) Nytt oralt, farmasöytisk preparat inneholdende magnesiumsalt av omeprazol
JP2002522501A5 (enExample)
RU2000100362A (ru) Применение специфического антагониста 5нт2 рецепторов для приготовления лекарств, пригодных для лечения синдрома апноэ во сне
HUP0000960A3 (en) Spray-dried paroxetine hydrochloride, process for it's preparation,use of the compound and pharmaceutical compositions containing the same
NZ502495A (en) Use of a specific antagonist of 5HT2 receptor antagonist for the preparation of medicines useful in the treatment of sleep apnoea syndrome
FR2793688B1 (fr) Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
IT1274571B (it) Procedimento per la preparazione di ¬r-(r*,r*)|-5-(3-clorofenil)-3- ¬2-(3,4-dimetossifenil)-1-metil-etil|-ossazolidin-2-one
NO20033184L (no) Anvendelse av forbindelsen (+)-<alfa>-(2,3-dimetoksyfenyl)-1- [2-(4-fluorfenyl)etyl]-4-piperidinmetanol
IL136231A (en) Process and intermediate for preparing cis-1-(2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)- phenoxy] ethyl) pyrrolidine
NO20004545L (no) FremgangsmÕte for fremstilling av (R)-<alfa>-(2,3- dimetoksyfenyl)-1-[2-(4-fluorofenyl)etyl]-4-piperidinmetanol
SI1052243T1 (en) Process for preparing (1R, 2S, 4R)-(-)-2-((2'-(N,N-dimethylamino)-ethoxy))-2-(phenyl)-1,7,7-tri-(methyl)-bicyclo(2.2.1)heptane and pharmaceutically acceptable acid addition salts thereof
NO980211D0 (no) Opplösning av 1-azabicyklo£2.2.2|oktan-3-amin,2-(difenylmetyl)-N-££2-metoksy-5-(1-metyletyl)fenyl|metyl|
EP1245562A4 (en) ALCOHOLS 5-THIA- "OMEGA" - (PHENYL SUBSTITUTED) - PROSTAGLANDIN E, PROCESS FOR THE PREPARATION OF SUCH ALCOHOLS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE ALCOHOLS AS ACTIVE INGREDIENT.
AU2253197A (en) Novel substituted N-Methyl-N-(4-(4-(1H-benzimidazol- 2-yl){1,4}diazepan-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases